Abstract

Despite many scientific advancements, we haven’t found satisfactory treatment for many dermatomes. The disFig.ment caused by these conditions is a source of distress. Pathophysiology of certain dermatomes roots from common pathophysiology. Though lots of medical treatments are available, however, they provide transient relief. Symptoms often re-appear after sometime.The conditions have a negative effect on overall quality of life of the patients leading to anxiety and depression in some cases. Usually these conditions take a long time to be asymptomatic only to relapse later. Janus kinase inhibitors (Jaknibs) are novel medications approved to be used in rheumatological conditions. Increasing evidences have shown their efficacy in many dermatological conditions such as psoriasis, vitiligo, atopic dermatitis, alopecia areata and a few others. Tofacitinib was first approved in 2012 by USFDA for the management of rheumatoid arthritis. Tofacitinib inhibits JAK1 and JAK3, reducing the signaling of pro-inflammatory cytokines. This inhibition affects various immune processes, which is beneficial in treating inflammatory and autoimmune conditions, including those affecting the skin.The drug is being accepted in dermatological conditions. In many other dermatoses, JAK inhibitors carry a promise in management. Cutaneous graftversus-host disease, erythema multiforme, dermatomyositis, chronic actinic dermatitis, and lupus and hypereosinophilic syndrome are few of such conditions. In the present review, we discuss the literature and evidence of the use of tofacitinib in dermatological conditions.

• 1.   Khandpur, S.; Sharma, V.K.; Sumanth, K. Topical immunomodulators in dermatology. Journal of Postgraduate Medicine 50(2):p 131-139, June 2004.
• 2.   Shreberk-Hassidim R., Ramot Y., Zlotogorski A. Janus kinase inhibitors in dermatology: A systematic review. J. Am Acad Dermatol 2017; 76:745-753.
• 3.   Samadi A., Ahmad Nasrollahi S., Hashemi A., Nassiri Kashani M., Firooz A. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: A review of literature. J. Dermatol Treat 2017; 28:476-483.
• 4.   Ghoreschi K., Gadina M. Jakpot! New small molecules in autoimmune and inflammatory diseases. Exp Dermatol2014;23:7-11.
• 5.   Kyle Tegtmeyer, Jeffrey Zhao, Off-label studies on tofacitinib in dermatology: A review, Journal of Dermatological Treatment, DOI: 10.1080/09546634.2019.1673877
• 6.   Fatemeh Zabihi, Mariam Cherri, Xiao Guo, Topical Delivery of Tofacitinib in Dermatology: The Promise of a Novel Therapeutic Class Using Biodegradable Dendritic Polyglycerol Sulfates Pharmaceuticals 2024, 17(1), 77; https://doi. org/10.3390/ph17010077
• 7.   Ciechanowicz, P.; Rakowska, A.; Sikora, M.; Rudnicka, L. JAK-inhibitors in dermatology. Current evidence and future applications. J. Dermatol. Treat. 2019, 30, 648–658
• 8.   Ghoreschi K., Jesson M.I., Li X., et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J. Immunol. 2011; 186(7):4234–4243.
• 9.   Schwartz D.M., Bonelli M., Gadina M., O’Shea J.J. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016; 12(1):25–36.
• 10.   Riese R.J., Krishnaswami S., Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol. 2010;24(4): 513–526.
• 11.   Hiroki L. Yamaguchi, Yuji Yamaguchi and Elena Peeva et al. Pathogenesis of Alopecia Areata and Vitiligo: Commonalities and Differences. Int. J. Mol. Sci. 2024, 25, 4409.
• 12.   Bachelez H., van de Kerkhof P.C., Strohal R., et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015; 386(9993):552–561.
• 13.   Papp K.A., Menter M.A., Abe M., et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J. Dermatol. 2015; 173(4):949–961.
• 14.   Leung D.Y., Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J. Allergy Clin Immunol. 2014; 134(4):769–779.
• 15.   Islam N., Leung P.S., Huntley A.C., Gershwin ME. The autoimmune basis of alopecia areata: A comprehensive review. Autoimmun Rev. 2015; 14(2):81–89.
• 16.   Chu S.Y., Chen Y.J., Tseng W.C., et al. Comorbidity profiles among patients with alopecia areata: the importance of onset age, a nationwide population-based study. J. Am Acad Dermatol. 2011; 65(5):949–956.
• 17.   Lee N.R., Kim B.K., Yoon N.Y., Lee S.Y., Ahn S.Y., Lee W.S. Differences in comorbidity profiles between early-onset and late-onset alopecia areata patients: a retrospective study of 871 Korean patients. Ann Dermatol. 2014;26(6):722–726.
• 18.   Huang K.P., Mullangi S., Guo Y., Qureshi A.A., Autoimmune QAA. Autoimmune, atopic, and mental health comorbid conditions associated with alopecia areata in the United States. JAMA Dermatol. 2013;149(7):789–794.
• 19.   Kennedy Crispin M., Ko JM., Craiglow B.G., et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016; 1(15):e89776.
• 20.   Liu L.Y., Craiglow B.G., Dai F., King B.A. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol. 2016 in press.
• 21.   Craiglow B.G., Liu L.Y., King B.A. Tofacitinib for the treatment of alopecia areata in adolescents. J Am Acad Dermatol. 2016 in press.
• 22.   Khadeejeh AL-smadi, Mohammad Imran, Yousuf Mohammed, Vitiligo: A Review of Aetiology, Pathogenesis, Treatment, and Psychosocial Impact Cosmetics 2023, 10(3), 84
• 23.   Xiu-kun Sun , An-qi Sheng , and Ai-e Xu. Tofacitinib for the Treatment of Refractory Progressive Vitiligo: ARetrospective Case Series. Dermatologic Therapy Volume 2024, Article ID 9944826, 5 pages. https://doi.org/10.1155/2024/9944826
• 24.   Liu L.Y., Strassner J.P., Refat M.A., Harris J.E., King B.A. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J. Am Acad Dermatol 2017; 77:675682.
• 25.   Kim S.R., Heaton H., Liu L.Y., King B.A. Rapid repigmentation of vitiligo using tofacitinib plus lowdose, narrowband UVB phototherapy. JAMA Dermatol 2018; 154:370.
• 26.   Welsch K., Holstein J., Laurence A., Ghoreschi K. Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors. Eur J. Immunol 2017; 47:1096-1107.
• 27.   Sonthalia S., Aggarwal P. Oral tofacitinib: Contemporary appraisal of its role in dermatology. Indian Dermatol Online J. 2019;10:503-18.
• 28.   Strober B.E., Gottlieb A.B., van de Kerkhof PCM, Puig L., Bachelez H., Chouela E., Imafuku S., Thaçi D., Tan H., Valdez H., Gupta P., Kaur M, Frajzyngier V., Wolk R. Benefit-risk profile of tofacitinib in patients with moderate-tosevere chronic plaque psoriasis: pooled analysis across six clinical trials. Br J. Dermatol. 2019 Jan; 180(1):67-75. doi: 10.1111/bjd.17149.
• 29.   Damsky W., King B.A. JAK inhibitors in dermatology: The promise of a new drug class. J. Am Acad Dermatol. 2017 Apr; 76(4):736-744. doi: 10.1016/j.jaad.2016.12.005.
• 30.   Busque S, Leventhal J., Brennan D.C., et al. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. Am J. Transplant. 2009; 9(8):1936–1945.
• 31.   Vincenti F., Tedesco Silva H., Busque S., et al. Randomized phase 2b trial of tofacitinib (CP- 690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant. 2012; 12(9):2446–2456.
• 32.   Vincenti F., Silva H.T., Busque S., et al. Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patients. Am J. Transplant. 2015; 15(6):1644–1653.
• 33.   William Damsky and Brett A. King. JAK inhibitors in dermatology: the promise of a new drug class. Am Acad Dermatol. 2017;76(4): 736– 744. doi:10.1016/j.jaad.2016.12.005.

Data Sharing Statement

Funding